Tuesday, August 4, 2026
Vertex tops Q2 estimates, raises 2026 revenue guidance
Vertex Pharmaceuticals reported Q2 2026 revenue of $3.33 billion on August 3, up 12% year over year, with net income of $1.10 billion and EPS of $4.34. The company raised full-year 2026 revenue guidance to $13.1-13.2 billion, driven partly by CASGEVY revenue growing 151% year over year to $76 million and JOURNAVX revenue roughly quadrupling to $50 million, with the two products now expected to contribute over $500 million combined for the year.